Of the 436 patients included in the intent-to-treat population, 129 received study therapy and had tumor assessments at ≥9 months of follow-up and were included in the TFI analysis; of these, 50 patients achieved a DR per the EAC (talimogene laherparepvec, n = 47; GM-CSF, n = 3) and 79 patients did not (talimogene laherparepvec, n = 65; GM-CSF, n = 14). This evidence concerns the gene CSF2 and neoplasm.